Almost 15,000 physicians, scientists, health-care professionals and industry representatives from around the globe presented research, treatment recommendations and advances toward a diabetes cure at the American Diabetes Association (ADA)’s 79th Scientific Sessions in San Francisco.

Novo Nordisk presented data from three separate studies that highlighted the efficacy of oral semaglutide, an investigational once-daily glucagon-like peptide-1 (GLP-1) analog in a pill. Additionally, data showed the efficacy of Merck’s Januvia on type 2 diabetes patients age 65 and older in comparison to the SGLT2 inhibitor dapagliflozin.

In people at high risk for type 1 diabetes, 14 days of therapy with the experimental drug teplizumab delayed development of the disease by a year or more.

Insulin-dependent patients with T2D saw a significant drop in blood sugar levels after wearing Abbott’s continuous glucose monitoring system compared with those who use routine fingerstick testing.

A new study found that taking 4,000 international units per day may double the amount of vitamin D in the blood, but it gives most people roughly the same chance of developing blood sugar problems as people who do not take the vitamin.

In veteran drug salesman Paul Hudson, Sanofi’s 100,000-plus employees are getting a new chief executive who relishes a good commercial fight.

Shares of Zealand Pharma A/S were up more than 2 percent after the company announced that dasiglucagon, a potential treatment for severe hypoglycemia, hit the mark in a Phase III study.

I got into Healthcare six years ago and canvassed major events to gain a consensus on what the future held.

Danish drugmaker Novo Nordisk beat first-quarter 2019 operating profit forecasts, helped by higher sales of the company’s biggest new drug hope, a treatment for type 2 diabetes.

Eli Lilly reported lower-than-expected first-quarter 2019 sales for the company’s top-selling diabetes drug Trulicity, due in part to patient affordability programs.